AstraZeneca's recent share price decline amidst market volatility is influenced by broader economic factors, including trade tensions. Despite key approvals for cancer treatments, the company faces challenges. Analysts project future revenue growth, with a 20.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing